Patients with IDC had high PD-L1 in tumours more frequently than patients with other subtypes (46.7% vs. 16.7%, P = 0.017) and it was also more frequent in B-cell Lymphoma 2 (bcl2) negative patients (58.8% vs. 36.0% in positive patients, P = 0.022). This evidence concerns the gene BCL2 and neoplasm.